Enanta Pharmaceuticals (ENTA) Free Cash Flow Growth (1y) (2013 - 2026)
Enanta Pharmaceuticals (ENTA) Free Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | 67.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.97% |
| Dec 31, 2025 | 39.16% |
| Sep 30, 2025 | 129.64% |
| Jun 30, 2025 | 253.75% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | 24.50% |
| Sep 30, 2024 | -19.09% |
| Jun 30, 2024 | 70.46% |
| Mar 31, 2024 | -100.88% |
| Dec 31, 2023 | 28.56% |
| Sep 30, 2023 | 18.72% |
| Jun 30, 2023 | -28.04% |
| Mar 31, 2023 | 41.93% |
| Dec 31, 2022 | -167.67% |
| Sep 30, 2022 | 17.95% |
| Jun 30, 2022 | -2.23% |
| Mar 31, 2022 | -462.82% |
| Dec 31, 2021 | 11.68% |
| Sep 30, 2021 | -38.64% |
| Jun 30, 2021 | -523.94% |